OGN Organon & Co. stock chart & analysis
Conviction 80HealthcareScan · Fri, Nov 6, 2026Organon & Co. (OGN) closed at $13.87 (+0.58%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 62, RS Rating 97, at a 52-week high, +93.2% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
OGN technical analysis
Trend
OGN is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 0.8% above the 50-day ($13.74) and 19.1% above the 200-day ($11.63). ADX(14) at 33 points to a strong, established trend. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 62, in the bullish half of its range. MACD crossed above its signal line 6 sessions ago. Its RS Rating of 97 puts its weighted 12-month performance ahead of about 97% of the US market, and its RS line is at a new high.
Volume and volatility
Volume on the latest session ran 1.0× its 20-day average. It trades about $33.0M a day on average. ATR(14) is $0.0439, 0.3% of price — its typical daily range. Chaikin Money Flow (-0.06) shows distribution.
Key levels
The chart pattern's support is $13.70 and its resistance $13.84. The 52-week range is $5.69 to $13.88, and price sits at the high. The VWAP anchored at the 52-week high is $13.83, below price.
Performance
OGN returned +0.1% (1 week), +0.7% (1 month), +1.7% (3 months), +3.8% (6 months), +117.1% (1 year), +93.2% (year to date).
About Organon & Co.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Pharmaceutical Preparations · Listed 2021 · 10,000 employees
Congress activity
Disclosed STOCK Act trades in OGN · 3 recent
Insider activity
SEC Form 4 transactions in OGN · open-market 1 buy · 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Arjona Ferreira Juan Camilo Head of R&D & CMO · Common Stock · 2026-08-11 | Exercise | 11.52K | — | 2026-08-11 | 2026-08-12 |
Arjona Ferreira Juan Camilo Head of R&D & CMO · Common Stock · 2026-08-11 | Tax | 4.13K | $56K | 2026-08-11 | 2026-08-12 |
Arjona Ferreira Juan Camilo Head of R&D & CMO · Restricted Stock Units · 2026-08-11 | Exercise | 11.52K | — | 2026-08-11 | 2026-08-12 |
Drinane Juliana Papa Head of Mfg & Supply · Common Stock · 2026-08-05 | Sell | 14.76K | $200K | 2026-08-05 | 2026-08-05 |
Holzbaur Lynette SVP and Corporate Controller · Common Stock · 2026-05-06 | Buy | 26.45K | $353K | 2026-05-06 | 2026-05-07 |
Holzbaur Lynette SVP and Corporate Controller · Common Stock · 2026-05-06 | Sell | 26.45K | $353K | 2026-05-06 | 2026-05-07 |
Holzbaur Lynette SVP and Corporate Controller · Common Stock · 2026-05-06 | Acquire | 45.939 | $0 | 2026-05-06 | 2026-05-07 |
SEC filings
EDGAR filings in OGN · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.